Attorney General Keith Ellison announced a settlement with Novo Nordisk that let's Minnesotans buy its insulin products for ...

The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Minnesotans prescribed insulin won’t pay more than $35 per month for it, after the conclusion of a lawsuit against three ...

For Novo Nordisk, a company still rooted in principles ... Its new fast-acting insulin Fiasp was also recently approved in Europe, but has faced delays in the US because of FDA safety questions.

Fast-acting insulins are designed to mimic the normal physiologic insulin response that occurs after meals and – if approved – Lilly's drug will compete most closely with Novo Nordisk's Fiasp ...

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...